Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005137/en/

Deciphera Pharmaceuticals Aktie

23,80 €
-0,85 %
Die Deciphera Pharmaceuticals Aktie rutscht heute leicht ab, verliert -0,85 %.
Die Deciphera Pharmaceuticals Aktie erhält starke Unterstützung mit mehreren Buy- und keiner Sell-Einschätzung.
Das Kursziel von 24 € für Deciphera Pharmaceuticals wurde mit dem heutigen Kurs von 23.8 € erreicht.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare